Assignee
RECODE THERAPEUTICS INC
US·7 granted patents·21 pending applications·6 citations·filing 2022–2025
Top patents by PatentIndex Score
28 records- 0190US12121610B2Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2023·Granted Oct 22, 2024·3 cites·32 claims
- 0289US12133923B2Lipid nanoparticle compositions and uses thereofRECODE THERAPEUTICS INC·Filed 2024·Granted Nov 5, 2024·2 cites·25 claims
- 0388US12337068B2Lipid nanoparticle compositions and uses thereofRECODE THERAPEUTICS INC·Filed 2024·Granted Jun 24, 2025·1 cites·28 claims
- 0482US2024374513A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0582US2024374514A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0682US2024390271A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0782US2024374512A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0882US2024390272A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0982US2024374511A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1080US12257318B2Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2024·Granted Mar 25, 2025·0 cites·30 claims
- 1179US12582611B2Lipid nanoparticle compositions and uses thereofRECODE THERAPEUTICS INC·Filed 2024·Granted Mar 24, 2026·0 cites·33 claims
- 1279US2025276091A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1379US2023338411A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1479US2024299310A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1579US2024277850A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1679US2024261432A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1778US2024245619A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1875US2024207178A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1972US2024398983A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2070US12364773B2Lipid nanoparticle compositions and uses thereofRECODE THERAPEUTICS INC·Filed 2024·Granted Jul 22, 2025·0 cites·39 claims
- 2168US2025019409A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2263US12553042B2Method for quantifying an amount of capped messenger RNARECODE THERAPEUTICS INC·Filed 2024·Granted Feb 17, 2026·0 cites·19 claims
- 2360US2024309376A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2459US2024216515A1Compositions and methods for targeted delivery to cellsRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2557US2024197641A1Compositions and methods for targeted systemic delivery to cellsRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2655US2025114477A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2755US2025288688A1Lipid nanoparticle compositions and uses thereofRECODE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2853US2024123087A1Polynucleotide compositions, related formulations, and methods of use thereofRECODE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →